{"id":4928,"date":"2024-12-10T17:04:45","date_gmt":"2024-12-10T16:04:45","guid":{"rendered":"https:\/\/www.evalii.de\/?p=4928"},"modified":"2024-12-10T17:05:15","modified_gmt":"2024-12-10T16:05:15","slug":"pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen","status":"publish","type":"post","link":"https:\/\/www.evalii.de\/en\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/","title":{"rendered":"Pharmacovigilance and Vigilance in the Pharmaceutical Industry: New Requirements for Monitoring Social Media and Digital Applications"},"content":{"rendered":"

Pharmacovigilance\/vigilance (PV) plays a central role in the pharmaceutical industry. It refers to the monitoring of medicines and medical devices after their approval to ensure patient safety. Traditionally, pharmacovigilance relies on clinical trial reports, medical journals or direct feedback from healthcare institutions. However, in the digital age, information flows are changing rapidly and social media and digital health applications have become important sources for monitoring adverse drug reactions (ADRs) and safety issues.<\/p>\n\n\n\n

Medical devices such as wearables and digital applications, such as mobile health apps, are increasingly coming onto the market and expanding the spectrum of products to be monitored<\/a> These new technologies, which often offer personalized healthcare services, generate enormous amounts of data containing potentially important information for pharmacovigilance. In this article, we examine how pharmacovigilance monitoring is changing in the age of social media and digital health applications and what challenges and solutions this presents for companies in the pharmaceutical industry.<\/p>\n\n\n\n

The Role of Social Media in Pharmacovigilance<\/strong><\/h2>\n\n\n\n

With the advent of social media such as Facebook, Twitter, Instagram and specialized patient forums, patient and consumer behavior has changed significantly. People are increasingly sharing their experiences with medicines and medical devices on social networks, often in real time. This presents both opportunities and challenges for pharmacovigilance. While traditional communication channels tend to be more formal, social media provides an unfiltered platform where patients can openly report adverse reactions and safety issues.<\/p>\n\n\n\n

The challenge is that this information is often scattered, unstructured and published in different languages. Patients rarely use the medically correct terms and it can be difficult to identify a relevant side effect from a simple experience report. Add to this the enormous amount of data generated daily through these platforms. Manual monitoring would be inefficient and hardly feasible.<\/p>\n\n\n\n

New requirements: medical devices and digital applications<\/strong><\/h2>\n\n\n\n

In addition to pharmaceuticals, medical devices and digital health applications are also becoming increasingly important. Wearables such as fitness trackers, smart blood glucose meters and blood pressure monitors that record health data in real time are becoming increasingly common. Mobile health applications that help patients monitor their health are also experiencing a real boom.<\/p>\n\n\n\n

These digital products must be monitored according to regulatory requirements. Medical device vigilance, which is closely related to pharmacovigilance, involves monitoring safety and performance issues. Manufacturers of digital health applications must ensure that their products are safe and do not have any undesirable effects. This requires continuous monitoring and proactive management of risks that may arise in the digital world.<\/p>\n\n\n\n

Another example is the increasing use of telemedicine and digital health services, where doctors communicate with patients via apps and digital platforms. This also creates new challenges for pharmacovigilance, as communication via these channels also needs to be monitored.<\/p>\n\n\n\n

The challenges of monitoring digital channels<\/strong><\/h2>\n\n\n\n

Monitoring social media and other digital channels brings with it a multitude of challenges. The biggest hurdles include:<\/p>\n\n\n\n

    \n
  1. data volume and speed<\/strong>: The sheer volume of posts, comments and reviews published daily on social platforms makes manual monitoring impossible. However, quickly identifying and acting on security-related information is crucial to respond to potential risks in a timely manner.<\/li>\n\n\n\n
  2. Unstructured data<\/strong>: Most information shared on social networks is unstructured. Patients often report their experiences in colloquial terms and rarely use the medically correct terms for adverse reactions. This makes it difficult to assess the relevance of this information for pharmacovigilance.<\/li>\n\n\n\n
  3. variety of channels<\/strong>: In addition to the classic social networks such as Facebook and Twitter, there are numerous specialized forums, patient communities, app store reviews, blogs and even comments in e-commerce portals such as Amazon. This multitude of sources must be monitored simultaneously to ensure that no safety-relevant information is overlooked.<\/li>\n\n\n\n
  4. linguistic diversity<\/strong>: The global availability of medicines and medical devices means that social media content is also published in different languages. Efficient monitoring must therefore be multilingual to ensure that all relevant posts are captured.<\/li>\n\n\n\n
  5. Regulatory requirements<\/strong>: Legal requirements for pharmacovigilance are strict and vary from country to country. Pharmaceutical companies must ensure that they collect, document and forward all relevant information to the competent authorities. This requires precise and continuous monitoring.<\/li>\n<\/ol>\n\n\n\n

    The use of artificial intelligence (AI) to overcome the challenges<\/strong><\/h2>\n\n\n\n

    To overcome these challenges, more and more companies in the pharmaceutical industry want to use artificial intelligence (AI) and machine learning. These technologies offer the ability to analyze large amounts of unstructured data in real time and automatically identify relevant information. Algorithms can be used to detect potentially safety-relevant contributions and classify them according to their relevance for pharmacovigilance.<\/p>\n\n\n\n

    A particularly effective approach is to use text mining and natural language processing (NLP) techniques to analyze unstructured data. These algorithms can learn to associate colloquial terms with medical terminology and identify potential ADRs. In addition, they can operate in near real-time, making it possible to react immediately to new information.<\/p>\n\n\n\n

    evalii\u00ae: A solution for digital pharmacovigilance and vigilance<\/strong><\/h2>\n\n\n\n

    In this context, evalii\u00ae<\/strong>, a software solution from Cross4Channel GmbH, has proven to be particularly effective. evalii\u00ae offers comprehensive monitoring of social media channels, digital platforms, app stores and wide channels. Using a specially developed algorithm, posts and comments are monitored in real time for their pharmacovigilance relevance and checked by a trained team.<\/p>\n\n\n\n

    This solution supports not only pharmacovigilance, but also vigilance for medical devices and digital health applications. With evalii\u00ae, companies can ensure that they capture, analyze and document all relevant information from the various digital channels.<\/p>\n\n\n\n

    In addition, it offers additional functions such as moderation of community posts. This means that the tool not only identifies potentially security-relevant posts, but also reacts to netiquette violations or legally problematic statements. evalii\u00ae thus helps to significantly reduce manual effort while increasing the efficiency and accuracy of monitoring processes.<\/p>\n\n\n\n

    Bottom line<\/strong><\/p>\n\n\n\n

    Pharmacovigilance and vigilance requirements have changed dramatically with the advent of social media, medical devices and digital health applications. Manual monitoring is no longer sufficient to cope with the enormous amount of data. Pharmaceutical companies must be able to capture relevant information in real time and respond quickly to potential risks.<\/p>\n\n\n\n

    The use of AI-based solutions offers a promising way to address these challenges. The future of pharmacovigilance is becoming increasingly digital, and solutions like evalii\u00ae are key to meeting the growing demands while ensuring patient safety.<\/p>","protected":false},"excerpt":{"rendered":"

    Pharmacovigilance\/vigilance (PV) plays a central role in the pharmaceutical industry. It refers to the monitoring of medicines and medical devices after their approval to ensure patient safety. Traditionally, pharmacovigilance is based on clinical trial reports, medical journals, or direct feedback from healthcare institutions. However, in the digital age, the [\u2026]<\/p>","protected":false},"author":4,"featured_media":4929,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-4928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmakovigilanz"],"yoast_head":"\nPharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen<\/title>\n<meta name=\"description\" content=\"Mit dem Aufkommen sozialer Medien wie Facebook, Twitter, Instagram und spezialisierter Patientenforen hat sich das Verhalten der Patienten und Verbraucher erheblich ver\u00e4ndert. Menschen teilen zunehmend ihre Erfahrungen mit Medikamenten und Medizinprodukten in sozialen Netzwerken, oft in Echtzeit.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.evalii.de\/en\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen\" \/>\n<meta property=\"og:description\" content=\"Mit dem Aufkommen sozialer Medien wie Facebook, Twitter, Instagram und spezialisierter Patientenforen hat sich das Verhalten der Patienten und Verbraucher erheblich ver\u00e4ndert. Menschen teilen zunehmend ihre Erfahrungen mit Medikamenten und Medizinprodukten in sozialen Netzwerken, oft in Echtzeit.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.evalii.de\/en\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\" \/>\n<meta property=\"og:site_name\" content=\"evalii - pharmacovigilance monitoring service\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T16:04:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T16:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"807\" \/>\n\t<meta property=\"og:image:height\" content=\"807\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Andrea Kurz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrea Kurz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\"},\"author\":{\"name\":\"Andrea Kurz\",\"@id\":\"https:\/\/www.evalii.de\/#\/schema\/person\/0184cbd8a0cb61b41889bea1a03d6137\"},\"headline\":\"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen\",\"datePublished\":\"2024-12-10T16:04:45+00:00\",\"dateModified\":\"2024-12-10T16:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\"},\"wordCount\":1149,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.evalii.de\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg\",\"articleSection\":[\"Pharmakovigilanz\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\",\"url\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\",\"name\":\"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen\",\"isPartOf\":{\"@id\":\"https:\/\/www.evalii.de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg\",\"datePublished\":\"2024-12-10T16:04:45+00:00\",\"dateModified\":\"2024-12-10T16:05:15+00:00\",\"description\":\"Mit dem Aufkommen sozialer Medien wie Facebook, Twitter, Instagram und spezialisierter Patientenforen hat sich das Verhalten der Patienten und Verbraucher erheblich ver\u00e4ndert. Menschen teilen zunehmend ihre Erfahrungen mit Medikamenten und Medizinprodukten in sozialen Netzwerken, oft in Echtzeit.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage\",\"url\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg\",\"contentUrl\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg\",\"width\":807,\"height\":807},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.evalii.de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.evalii.de\/#website\",\"url\":\"https:\/\/www.evalii.de\/\",\"name\":\"evalii - pharmacovigilance monitoring service\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.evalii.de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.evalii.de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.evalii.de\/#organization\",\"name\":\"evalii - pharmacovigilance monitoring service\",\"url\":\"https:\/\/www.evalii.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.evalii.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/02\/cropped-evalii_logo_partial-white-e1709128348839.png\",\"contentUrl\":\"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/02\/cropped-evalii_logo_partial-white-e1709128348839.png\",\"width\":200,\"height\":82,\"caption\":\"evalii - pharmacovigilance monitoring service\"},\"image\":{\"@id\":\"https:\/\/www.evalii.de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.evalii.de\/#\/schema\/person\/0184cbd8a0cb61b41889bea1a03d6137\",\"name\":\"Andrea Kurz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.evalii.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/731668cbc712205ca24030d4f9ef09f0d6f76b35cf399120f15285057cf20781?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/731668cbc712205ca24030d4f9ef09f0d6f76b35cf399120f15285057cf20781?s=96&d=mm&r=g\",\"caption\":\"Andrea Kurz\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacovigilance and Vigilance in the Pharmaceutical Industry: New Requirements for Monitoring Social Media and Digital Applications","description":"With the rise of social media platforms like Facebook, Twitter, Instagram, and specialized patient forums, the behavior of patients and consumers has changed significantly. People are increasingly sharing their experiences with medications and medical devices on social networks, often in real time.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.evalii.de\/en\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/","og_locale":"en_US","og_type":"article","og_title":"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen","og_description":"Mit dem Aufkommen sozialer Medien wie Facebook, Twitter, Instagram und spezialisierter Patientenforen hat sich das Verhalten der Patienten und Verbraucher erheblich ver\u00e4ndert. Menschen teilen zunehmend ihre Erfahrungen mit Medikamenten und Medizinprodukten in sozialen Netzwerken, oft in Echtzeit.","og_url":"https:\/\/www.evalii.de\/en\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/","og_site_name":"evalii - pharmacovigilance monitoring service","article_published_time":"2024-12-10T16:04:45+00:00","article_modified_time":"2024-12-10T16:05:15+00:00","og_image":[{"width":807,"height":807,"url":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg","type":"image\/jpeg"}],"author":"Andrea Kurz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Andrea Kurz","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#article","isPartOf":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/"},"author":{"name":"Andrea Kurz","@id":"https:\/\/www.evalii.de\/#\/schema\/person\/0184cbd8a0cb61b41889bea1a03d6137"},"headline":"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen","datePublished":"2024-12-10T16:04:45+00:00","dateModified":"2024-12-10T16:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/"},"wordCount":1149,"commentCount":0,"publisher":{"@id":"https:\/\/www.evalii.de\/#organization"},"image":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg","articleSection":["Pharmakovigilanz"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/","url":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/","name":"Pharmacovigilance and Vigilance in the Pharmaceutical Industry: New Requirements for Monitoring Social Media and Digital Applications","isPartOf":{"@id":"https:\/\/www.evalii.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage"},"image":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg","datePublished":"2024-12-10T16:04:45+00:00","dateModified":"2024-12-10T16:05:15+00:00","description":"With the rise of social media platforms like Facebook, Twitter, Instagram, and specialized patient forums, the behavior of patients and consumers has changed significantly. People are increasingly sharing their experiences with medications and medical devices on social networks, often in real time.","breadcrumb":{"@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#primaryimage","url":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg","contentUrl":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/12\/PVundVinderPharma.jpg","width":807,"height":807},{"@type":"BreadcrumbList","@id":"https:\/\/www.evalii.de\/2024\/12\/10\/pharmakovigilanz-und-vigilanz-in-der-pharmaindustrie-neue-anforderungen-bei-der-ueberwachung-von-social-media-und-digitalen-anwendungen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.evalii.de\/"},{"@type":"ListItem","position":2,"name":"Pharmakovigilanz und Vigilanz in der Pharmaindustrie: Neue Anforderungen bei der \u00dcberwachung von Social Media und digitalen Anwendungen"}]},{"@type":"WebSite","@id":"https:\/\/www.evalii.de\/#website","url":"https:\/\/www.evalii.de\/","name":"evalii - pharmacovigilance monitoring service","description":"","publisher":{"@id":"https:\/\/www.evalii.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.evalii.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.evalii.de\/#organization","name":"evalii - pharmacovigilance monitoring service","url":"https:\/\/www.evalii.de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.evalii.de\/#\/schema\/logo\/image\/","url":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/02\/cropped-evalii_logo_partial-white-e1709128348839.png","contentUrl":"https:\/\/www.evalii.de\/wp-content\/uploads\/2024\/02\/cropped-evalii_logo_partial-white-e1709128348839.png","width":200,"height":82,"caption":"evalii - pharmacovigilance monitoring service"},"image":{"@id":"https:\/\/www.evalii.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.evalii.de\/#\/schema\/person\/0184cbd8a0cb61b41889bea1a03d6137","name":"Andrea Kurz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.evalii.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/731668cbc712205ca24030d4f9ef09f0d6f76b35cf399120f15285057cf20781?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/731668cbc712205ca24030d4f9ef09f0d6f76b35cf399120f15285057cf20781?s=96&d=mm&r=g","caption":"Andrea Kurz"}}]}},"_links":{"self":[{"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/posts\/4928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/comments?post=4928"}],"version-history":[{"count":1,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/posts\/4928\/revisions"}],"predecessor-version":[{"id":4930,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/posts\/4928\/revisions\/4930"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/media\/4929"}],"wp:attachment":[{"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/media?parent=4928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/categories?post=4928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.evalii.de\/en\/wp-json\/wp\/v2\/tags?post=4928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}